Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Gilead Sciences International Limited
Primary Biliary Cholangitis
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion
Gilead Sciences International Limited
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting
1 trial -
Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM ISL/LEN, ISLATRAVIR/LENACAPAVIR, ISLATRAVIR/LENACAPAVIR, PTM Biktarvy
Gilead Sciences International Limited
HIV-1 Infection
1 trial -
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences International Limited
Non-small cell lung cancer
1 trial -
GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182
Gilead Sciences International Limited
HIV-1 Infection
1 trial -
GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720
Gilead Sciences International Limited
HIV-1 Infection
1 trial -
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
Gilead Sciences International Limited
COVID-19
1 trial -
Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.
Gilead Sciences International Limited
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
1 trial -
HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences International Limited
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Xeloda 500 mg film-coated tablets, Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences International Limited
Triple Negative Breast Cancer
1 trial -
LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE,
Gilead Sciences International Limited
HIV-1 Infection
1 trial -
PACLITAXEL , Trodelvy 200 mg powder for concentrate for solution for infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion
Gilead Sciences International Limited
Recurrent or Persistent Endometrial Cancer
1 trial -
PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS
Gilead Sciences International Limited
HIV-1 infection
1 trial -
Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Gilead Sciences International Limited
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1 trial -
Placebo to match 10 mg, Placebo to match 5 mg
Gilead Sciences International Limited
Primary Biliary Cholangitis
1 trial -
Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS
Gilead Sciences International Limited
HIV-1 Infection
1 trial -
TENOFOVIR DISOPROXIL AND EMTRICITABINE , Sunlenca 300 mg film-coated tablets, Sunlenca 464 mg solution for injection
Gilead Sciences International Limited
Human Immunodeficiency Virus (HIV-1) infection
1 trial -
Viread 245 mg film-coated tablets, Viread 123 mg film-coated tablets, Viread 204 mg film-coated tablets, PTM Tenofovir DF, Viread 163 mg film-coated tablets, Viread 33 mg/g granules
Gilead Sciences International Limited
Hepatitis B Infection
1 trial -
Zimberelimab, CARBOPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, CISPLATIN , PACLITAXEL , Abraxane 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion
Gilead Sciences International Limited
Metastatic Non–Small Cell Lung Cancer
1 trial -
Carboplatin 10 mg/ml Concentrate for Solution for Infusion, DOMVANALIMAB, Paclitaxel 6 mg/ml concentrate for solution for infusion, Zimberelimab
Gilead Sciences International Limited
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
GS-4321 PLACEBO
Gilead Sciences International Limited
Chronic Hepatitis Delta.
1 trial -
Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences International Limited
Locally Advanced/Metastatic Urothelial Cancer
1 trial -
PTM 75 mg Tablets, GS-1427, GS-1427, PTM 100 mg Tablets, GS-1427, PTM 25 mg Tablets
Gilead Sciences International Limited
Ulcerative Colitis (UC)
1 trial -
Pemetrexed Ribosepharm 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatine Hikma 450 mg/45 ml Infusionslösung, Pemetrexed Hexal 25 mg/ml infuusiokonsentraatti, liuosta varten, Cisplatine 1 mg/ml PCH, concentraat voor oplossing voor infusie, Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, DOMVANALIMAB, Pemetrexed NeoCorp 25 mg/ml Konzentrat zur Herstellung einer Infusionslös
Gilead Sciences International Limited
Advanced Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources